Yang H, Liu H, Chen Y, et al. - Patients with locally advanced esophageal squamous cell carcinoma (ESCC) exhibited a survival benefit in the long-term in correlation with undergoing neoadjuvant chemoradiotherapy followed by surgery compared with surgery alone.

• A multicenter open-label randomized phase 3 clinical trial, the Neoadjuvant Chemoradiotherapy for Esophageal Cancer 5010 study.

• Participants were 451 patients with locally advanced ESCC.

• Significantly improved 5-year overall survival of 59.9% was observed in correlation with receiving treatment with neoadjuvant chemoradiotherapy plus surgery relative to 49.1% noted after undergoing surgery alone.

• In addition, improved disease-free survival was observed with undergoing neoadjuvant chemoradiotherapy plus surgery.

• Hence, this combination may be considered a standard of care in this patient population.